Bibliometric Analysis of Global Research on Transient Receptor Potential Vanilloid 1 in the Field of Pain

References

• Raja SN, Carr DB, Cohen M, et al. The revised international association for the study of pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–1982. doi:10.1097/j.pain.0000000000001939
   PubMed Web of Science ®Google Scholar
• Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health. 2011;11:770. doi:10.1186/1471-2458-11-770
   PubMed Web of Science ®Google Scholar
• Henschke N, Kamper SJ, Maher CG. The epidemiology and economic consequences of pain. Mayo Clin Proc. 2015;90(1):139–147. doi:10.1016/j.mayocp.2014.09.010
   PubMed Web of Science ®Google Scholar
• Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol. 2011;12(3):218. doi:10.1186/gb-2011-12-3-218
   PubMed Web of Science ®Google Scholar
• Premkumar LS, Abooj M. TRP channels and analgesia. Life Sci. 2012;92(8–9):415–424. doi:10.1016/j.lfs.2012.08.010
   PubMed Web of Science ®Google Scholar
• Moriello AS, De Petrocellis L, Vitale RM. Fluorescence-based assay for TRPV1 channels. Methods Mol Biol. 2023;2576:119–131. doi:10.1007/978-1-0716-2728-0_9
   PubMedGoogle Scholar
• Hu J, Gao M, Zhang Y, et al. Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists. Bioorg Chem. 2021;115:105229. doi:10.1016/j.bioorg.2021.105229
   PubMed Web of Science ®Google Scholar
• Ledford H, Callaway E. Medicine Nobel goes to scientists who discovered biology of senses. Nature. 2021;598(7880):246. doi:10.1038/d41586-021-01283-6
   PubMed Web of Science ®Google Scholar
• Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816–824. doi:10.1038/39807
   PubMed Web of Science ®Google Scholar
• Katz B, Zaguri R, Edvardson S, et al. Nociception and pain in humans lacking functional TRPV1 channel. J Clin Invest. 2023;133(3):e153558. doi:10.1172/JCI153558
   PubMedGoogle Scholar
• Iftinca M, Defaye M, Altier CAO. TRPV1-targeted drugs in development for human pain conditions. Drugs. 2021;81(1):7–27. doi:10.1007/s40265-020-01429-2
   PubMed Web of Science ®Google Scholar
• Akhilesh UA, Gadepalli A, Gadepalli A, et al. Unlocking the potential of TRPV1 based siRNA therapeutics for the treatment of chemotherapy-induced neuropathic pain. Life Sci. 2022;288:120187. doi:10.1016/j.lfs.2021.120187
   PubMed Web of Science ®Google Scholar
• Bogdan DM, Studholme K, DiBua A, et al. FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain. Sci Rep. 2022;12(1):9241. doi:10.1038/s41598-022-13284-0
   PubMed Web of Science ®Google Scholar
• Fang D, Kong LY, Cai J, et al. Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model. Pain. 2015;156(6):1124–1144. doi:10.1097/j.pain.0000000000000158
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3
   PubMed Web of Science ®Google Scholar
• Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. JASIST. 2006;57(3):359–377. doi:10.1002/asi.20317
   Web of Science ®Google Scholar
• Takayama Y, Tominaga M. Involvement of TRPV1-ANO1 interactions in pain-enhancing mechanisms. Adv Exp Med Biol. 2018;1099:29–36. doi:10.1007/978-981-13-1756-9_3
   PubMed Web of Science ®Google Scholar
• Tominaga M. Activation and regulation of nociceptive transient receptor potential (TRP) channels, TRPV1 and TRPA1. Yakugaku Zasshi. 2010;130(3):289–294. doi:10.1248/yakushi.130.289
   PubMed Web of Science ®Google Scholar
• Takayama Y, Derouiche S, Maruyama K, Tominaga M. Emerging perspectives on pain management by modulation of TRP channels and ANO1. Int J Mol Sci. 2019;20(14):3411. doi:10.3390/ijms20143411
   PubMed Web of Science ®Google Scholar
• Julius D. TRP channels and pain. Annu Rev Cell Dev Biol. 2013;29:355–384. doi:10.1146/annurev-cellbio-101011-155833
   PubMed Web of Science ®Google Scholar
• Liao M, Cao E, Julius D, et al. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. Nature. 2013;504(7478):107–112. doi:10.1038/nature12822
   PubMed Web of Science ®Google Scholar
• Cao E, Liao M, Cheng Y, et al. TRPV1 structures in distinct conformations reveal activation mechanisms. Nature. 2013;504(7478):113–118. doi:10.1038/nature12823
   PubMed Web of Science ®Google Scholar
• Vandewauw I, De Clercq K, Mulier M, et al. A TRP channel trio mediates acute noxious heat sensing. Nature. 2018;555(7698):662–666. doi:10.1038/nature26137
   PubMed Web of Science ®Google Scholar
• Marrone MC, Morabito A, Giustizieri M, et al. TRPV1 channels are critical brain inflammation detectors and neuropathic pain biomarkers in mice. Nat Commun. 2017;8:15292. doi:10.1038/ncomms15292
   PubMed Web of Science ®Google Scholar
• Weng HJ, Patel KN, Jeske NA, et al. Tmem100 is a regulator of TRPA1-TRPV1 complex and contributes to persistent pain. Neuron. 2015;85(4):833–846. doi:10.1016/j.neuron
   PubMed Web of Science ®Google Scholar
• Naik GG, Uniyal A, Chouhan D, et al. Natural products and some semi-synthetic analogues as potential TRPV1 ligands for attenuating neuropathic pain. Curr Pharm Biotechnol. 2022;23(6):766–786. doi:10.2174/1389201022666210719155931
   PubMed Web of Science ®Google Scholar
• Akhilesh T, Uniyal A, Gadepalli A, et al. Unlocking the potential of TRPV1 based siRNA therapeutics for the treatment of chemotherapy-induced neuropathic pain. Life Sci. 2022;288:120187. doi:10.1016/j.lfs.2021.120187
   PubMed Web of Science ®Google Scholar
• Lee H, Ahn S, Ann J, et al. Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain. Eur J Med Chem. 2019;182:111634. doi:10.1016/j.ejmech.2019.111634
   PubMed Web of Science ®Google Scholar
• Kim C, Ann J, Lee S, et al. Discovery of 2- (3,5-difluoro-4 methylsulfonaminophenyl) propanamides as potent TRPV1 antagonists. Bioorg Med Chem Lett. 2018;28(14):2539–2542. doi:10.1016/j.bmcl.2018.05.043
   PubMed Web of Science ®Google Scholar
• Ann J, Kim HS, Thorat SA, et al. Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist as strong topical analgesic. J Med Chem. 2020;63(1):418–424. doi:10.1021/acs.jmedchem.9b01046
   PubMed Web of Science ®Google Scholar
• Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 1998;21(3):531–543. doi:10.1016/s0896-6273(00)80564-4
   PubMed Web of Science ®Google Scholar
• Tominaga M, Julius D. Capsaicin receptor in the pain pathway. Jpn J Pharmacol. 2000;83(1):20–24. doi:10.1254/jjp.83.20
   PubMedGoogle Scholar
• Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 2000;288(5464):306–313. doi:10.1126/science.288.5464.306
   PubMed Web of Science ®Google Scholar
• Miller BA, Zhang W. TRP channels as mediators of oxidative stress. Adv Exp Med Biol. 2011;704:531–544. doi:10.1007/978-94-007-0265-3_29
   PubMed Web of Science ®Google Scholar
• Özdemir ÜS, Nazıroğlu M, Şenol N, Ghazizadeh V. Hypericum perforatum attenuates spinal cord injury-induced oxidative stress and apoptosis in the dorsal root ganglion of rats: involvement of TRPM2 and TRPV1 channels. Mol Neurobiol. 2016;53(6):3540–3551. doi:10.1007/s12035-015-9292-1
   PubMed Web of Science ®Google Scholar
• Zhu Y, Colak T, Fau - Shenoy M, et al. Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis. Gastroenterology. 2011;141(1):370–377. doi:10.1053/j.gastro.2011.03.046
   PubMed Web of Science ®Google Scholar
• Spekker EA-O, Körtési T, Vécsei L. TRP channels: recent development in translational research and potential therapeutic targets in migraine. Int J Mol Sci. 2022;24(1):700. doi:10.3390/ijms24010700
   PubMed Web of Science ®Google Scholar
• Ruiz-Cantero MC, Cortés-Montero E, Jain A, et al. The sigma-1 receptor curtails endogenous opioid analgesia during sensitization of TRPV1 nociceptors. Br J Pharmacol. 2023;180(8):1148–1167. doi:10.1111/bph.16003
   PubMed Web of Science ®Google Scholar
• Lowe H, Toyang N, Steele B, et al. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):9472. doi:10.3390/ijms22179472
   PubMed Web of Science ®Google Scholar
• Blanton H, Reddy PH, Benamar K. Chronic pain in Alzheimer’s disease: endocannabinoid system. Exp Neurol. 2023;360:114287. doi:10.1016/j.expneurol.2022.114287
   PubMed Web of Science ®Google Scholar
• Fitzgibbon M, Finn DP, Roche M. High times for painful blues: the endocannabinoid system in pain-depression comorbidity. Int J Neuropsychoph. 2015;19(3):yv095. doi:10.1093/ijnp/pyv095
   Web of Science ®Google Scholar
• Storozhuk MV, Zholos AV. TRP channels as novel targets for endogenous ligands: focus on endocannabinoids and nociceptive signalling. Curr Neuropharmacol. 2018;16(2):137–150. doi:10.2174/1570159X15666170424120802
   PubMed Web of Science ®Google Scholar
• Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2019;11:487. doi:10.3389/fnmol.2018.00487
   PubMed Web of Science ®Google Scholar
• Maldonado R, Baños JE, Cabañero D. The endocannabinoid system and neuropathic pain. Pain. 2016;157 Suppl 1:S23–S32. doi:10.1097/j.pain.0000000000000428
   PubMed Web of Science ®Google Scholar
• Anand P, Whiteside G, Fowler CJ, et al. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60(1):255–266. doi:10.1016/j.brainresrev.2008.12.003
   PubMedGoogle Scholar
• Greco R, Demartini C, Zanaboni AM, et al. The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache. 2022;62(3):227–240. doi:10.1111/head.14267
   PubMed Web of Science ®Google Scholar
• Mecca CM, Chao D, Yu G, et al. Dynamic change of endocannabinoid signaling in the medial prefrontal cortex controls the development of depression after neuropathic pain. J Neurosci. 2021;41(35):7492–7508. doi:10.1523/JNEUROSCI.3135-20.2021
   PubMed Web of Science ®Google Scholar
• Wilkinson N. The ups and downs of endocannabinoid signaling in chronic pain-induced depression. J Neurosci. 2022;42(11):2143–2145. doi:10.1523/JNEUROSCI.2212-21.2022
   PubMed Web of Science ®Google Scholar
• Chen SR, Pan HL. Effect of systemic and intrathecal gabapentin on allodynia in a new rat model of postherpetic neuralgia. Brain Res. 2005;1042(1):108–113. doi:10.1016/j.brainres.2005.02.024
   PubMed Web of Science ®Google Scholar
• Wu CH, Lv ZT, Zhao Y, et al. Electroacupuncture improves thermal and mechanical sensitivities in a rat model of postherpetic neuralgia. Mol Pain. 2013;9:18. doi:10.1186/1744-8069-9-18
   PubMed Web of Science ®Google Scholar
• Nurmikko T, Bowsher D. Somatosensory findings in postherpetic neuralgia. J Neurol Neurosurg Psychiatry. 1990;52(2):135–141. doi:10.1136/jnnp.53.2.135
   Google Scholar
• Gao Y, Cao E, Julius D, et al. TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. Nature. 2016;534(7607):347–351. doi:10.1038/nature17964
   PubMed Web of Science ®Google Scholar
• Patapoutian A, Tate S, Woolf CJ. Transient receptor potential channels: targeting pain at the source. Nat Rev Drug Discov. 2009;8(1):55–68. doi:10.1038/nrd2757
   PubMed Web of Science ®Google Scholar
• Kim YH, Back SK, Davies A, et al. TRPV1 in GABAergic interneurons mediates neuropathic mechanical allodynia and disinhibition of the nociceptive circuitry in the spinal cord. Neuron. 2012;74(4):640–647. doi:10.1016/j.neuron.2012.02.039
   PubMed Web of Science ®Google Scholar
• Li Y, Adamek P, Zhang H, et al. The cancer chemotherapeutic paclitaxel increases human and rodent sensory neuron responses to TRPV1 by activation of TLR4. J Neurosci. 2015;35(39):13487–13500. doi:10.1523/JNEUROSCI.1956-15.2015
   PubMed Web of Science ®Google Scholar
• Basso L, Altier C. Transient receptor potential channels in neuropathic pain. Curr Opin Pharmacol. 2017;32:9–15. doi:10.1016/j.coph.2016.10.002
   PubMed Web of Science ®Google Scholar
• Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–284. doi:10.1016/j.cell.2009.09.028
   PubMed Web of Science ®Google Scholar
• Moran MM, McAlexander MA, Bíró T, et al. Transient receptor potential channels as therapeutic targets. Nat Rev Drug Discov. 2011;10(8):601–620. doi:10.1038/nrd3456
   PubMed Web of Science ®Google Scholar
• Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug Discov Today. 2009;14(1–2):56–67. doi:10.1016/j.drudis.2008.11.005
   PubMed Web of Science ®Google Scholar
• Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res Rev. 2009;60(1):267–277. doi:10.1016/j.brainresrev.2008.12.006
   PubMed Web of Science ®Google Scholar
• Karashima Y, Talavera K, Everaerts W, et al. TRPA1 acts as a cold sensor in vitro and in vivo. Proc Natl Acad Sci USA. 2009;106(4):1273–1278. doi:10.1073/pnas.0808487106
   PubMed Web of Science ®Google Scholar
• Kremeyer B, Lopera F, Cox JJ, et al. A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron. 2010;66(5):671–680. doi:10.1016/j.neuron.2010.04.030
   PubMed Web of Science ®Google Scholar
• Cavanaugh DJ, Chesler AT, Bráz JM, et al. Restriction of transient receptor potential vanilloid-1 to the peptidergic subset of primary afferent neurons follows its developmental downregulation in nonpeptidergic neurons. J Neurosci. 2011;31(28):10119–10127. doi:10.1523/JNEUROSCI.1299-11.2011
   PubMed Web of Science ®Google Scholar
• ONeill J, Brock C, Olesen AE, et al. Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol Rev. 2012;64(4):939–971. doi:10.1124/pr.112.006163
   PubMed Web of Science ®Google Scholar
• Nilius B, Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev. 2014;66(3):676–814. doi:10.1124/pr.113.008268
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol. 2014;171(10):2474–2507. doi:10.1111/bph.12414
   PubMed Web of Science ®Google Scholar
• Usoskin D, Furlan A, Islam S, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci. 2015;18(1):145–153. doi:10.1038/nn.3881
   PubMed Web of Science ®Google Scholar
• Paulsen CE, Armache JP, Gao Y, et al. Structure of the TRPA1 ion channel suggests regulatory mechanisms. Nature. 2015;520(7548):511–517. doi:10.1038/nature14367
   PubMed Web of Science ®Google Scholar
• Yang F, Zheng J. Understand spiciness: mechanism of TRPV1 channel activation by capsaicin. Protein Cell. 2017;8(3):169–177. doi:10.1007/s13238-016-0353-7
   PubMed Web of Science ®Google Scholar
• Moran MM, Szallasi A. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. Br J Pharmacol. 2018;175(12):2185–2203. doi:10.1111/bph.14044
   PubMed Web of Science ®Google Scholar
• Gouin O, L’Herondelle K, Lebonvallet N, et al. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization. Protein Cell. 2017;8(9):644–661. doi:10.1007/s13238-017-0395-5
   PubMed Web of Science ®Google Scholar
• Moore C, Gupta R, Jordt SE, et al. Regulation of pain and itch by TRP channels. Neurosci Bull. 2018;34(1):120–142. doi:10.1007/s12264-017-0200-8
   PubMed Web of Science ®Google Scholar
• Garami A, Shimansky YP, Rumbus Z, et al. Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: insights from mathematical modeling and meta-analysis. Pharmacol Ther. 2020;208:107474. doi:10.1016/j.pharmthera.2020.107474.
   PubMed Web of Science ®Google Scholar